Seattle Genetics

Seattle Genetics, Bayer in ADC collaboration

Wednesday, June 26, 2013

Biotech Seattle Genetics has entered into an antibody-drug conjugate (ADC) collaboration with Bayer HealthCare. Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics’ auristatin-based ADC technology with antibodies to several oncology targets. Seattle Genetics also is eligible to receive up to $500 million in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration. Bayer is responsible for research, product development, manufacturing and commercialization of all products. 

[Read More]

Icon, DIA to deliver new educational product

Monday, February 11, 2013

Icon,a global provider of outsourced development, has formed a collaboration with DIA, a neutral, global, professional, member-driven association of nearly 18,000 pharmaceutical, biotechnology, and medical device professionals, to deliver the first solution-provider webinar, which offers free access to knowledge and innovative solutions to overcome some of the key challenges in medical product development.

[Read More]

Seattle Genetics, Millennium, Ventana collaborate on companion diagnostic test for Adcetris

Friday, April 13, 2012

Seattle Genetics and Millennium, a subsidiary of Takeda Pharmaceutical, have formed a collaboration with Ventana Medical Systems, a member of the Roche Group, through which Ventana will seek to develop, manufacture and commercialize a molecular companion diagnostic test with the goal of identifying patients who might respond to treatment with Adcetris based on CD30 expression levels in their tissue specimens.

[Read More]

Interim data released on phase I Adcetris trial

Friday, January 27, 2012

Seattle Genetics and Millennium, the Takeda oncology company, released interim results from 32 patients treated to date in a phase I clinical trial of Adcetris (brentuximab vedotin) administered in combination or sequentially with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma (sALCL) and other CD30-positive mature T-cell lymphoma patients.

[Read More]